Company

NurExone Biologic Inc. is a publicly-traded biopharmaceutical company, listed on the Toronto Stock Exchange (TSXV: NRX), the OTCQB Venture Market (OTCQB:NRXBF) and Frankfurt Stock Exchange (TSXV: NRX). Developing and commercializing the ExoTherapy platform for production of exosome-loaded nanodrugs.

The Company operates according to two business lines:

• Using our ExoTherapy platform to develop a first exosome-loaded nanodrug, ExoPTEN, for acute Spinal Cord Injuries (SCI) targeted at a global market projected at $2.9 billion dollars.
• Partnerships and licensing of the ExoTherapy platform to the global biopharmaceutical industry targeting other diseases and indications.